CA-170 is an orally delivered dual inhibitor ofVISTAandPD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 andVISTAwith selectivity over otherimmune checkpoint proteinsas well as a broad panel of receptors and enzymes^[1][2].

PD-1^[1]

CA-170 exhibits potent functional activity in rescuing T-cell proliferation and effector functions, while showing selectivity against other immune checkpoint proteins as well as in a broad panel of receptors and enzymes^[2].

360.32

Solid

C₁₂H₂₀N₆O₇

1673534-76-3

Room temperature in continental US; may vary elsewhere.

DMSO : 28.5 mg/mL(79.10 mM;Need ultrasonic and warming)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 5% DMSO    40%PEG300   5%Tween-80   50% saline

  Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
• 2.

  请依序添加每种溶剂： 5% DMSO    95% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
• 3.

  请依序添加每种溶剂： 1% DMSO    99% saline

  Solubility: ≥ 0.5 mg/mL (1.39 mM); Clear solution